[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pusan National University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,69,101,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643904","mobile-restriction-on-dopamine-transporter-100643904",false,"NCT07663474","Mobile Restriction on Dopamine Transporter","Inclusion Criteria:\n\n* Healthy subjects with daily use of mobile phone (IPhone)\n* Accessible with \"Screentime\" application\n\nExclusion Criteria:\n\n* Neuropsychiatric disease\n* Subjects who have medications for mental illness\n* Subjects who cannot undergo PET scans\n* Subjects who cannot participate 4 weeks of this study",true,"ALL","19 Years","40 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Restriction of mobile phone use for 2wks and undergo PET scanning for DAT bindinng. Free use of mobile phone use for 2wks and undergo PET scanning for DAT bindinng.",[27,28],"Addiction","SMARTPHONE OWNER","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2026-05-01",{"date":37,"type":21},"2030-12-31",{"name":39,"class":40},"Pusan National University Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":5},"100577963","early-feeding-versus-delayed-feeding-after-colorectal-endoscopic-submucosal-dissection-100577963","NCT06805123","Early Feeding Versus Delayed Feeding After Colorectal Endoscopic Submucosal Dissection","Comparison of Clinical Outcomes According to Timing of Dietary Restart After Colorectal Endoscopic Submucosal Dissection: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria: Patients undergoing colorectal endoscopic submucosal dissection for the following lesions:\n\n* Differentiated early colorectal cancer confined to the mucosa, without ulcers, and measuring ≤5 cm\n* Laterally spreading tumors measuring ≥2 cm\n* Sessile polyps measuring ≥2 cm\n* Adenomas accompanied by fibrosis\n* Differentiated early cancer of the colon or rectum without lymph node metastasis, aside from those covered by partial self-payment insurance (Korean National Health insurance)\n* Submucosal tumors of the colon or rectum\n* Patients who have signed the consent form to participate in this study\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Patients with unresolved colorectal cancer\n* Patients with non-remissive inflammatory bowel disease (IBD)\n* Patients with blood coagulation disorders\n* Patients with a prothrombin time (PT) INR ≥ 1.5 despite medical correction\n* Pregnant patients\n* Patients who refuse to participate in this study","18 Years",{"count":51,"type":21},204,[24],"Currently, there are no clear guidelines regarding the optimal timing for dietary restart after gastrointestinal endoscopic submucosal dissection (ESD). While several studies have addressed upper gastrointestinal ESD, a meta-analysis reported that early feeding, initiated within one day after the procedure, showed no statistically significant difference in complication rates compared to delayed feeding initiated after two or more days. Moreover, early feeding was associated with shorter hospital stays and higher patient satisfaction. However, to the best of our knowledge, no studies have investigated early feeding in colorectal ESD.\n\nOn the other hand, in the context of surgical procedures involving the gastrointestinal tract, several studies suggest that early feeding may offer clinical advantages over delayed feeding.\n\nThe aim of this study is to explore the optimal timing for dietary restart following colorectal ESD. In the early feeding group (\\\u003C24 hours), patients begin water intake if no abnormalities are observed during a follow-up examination conducted two hours post-procedure. If no further issues arise after an additional two hours, a liquid diet is initiated. In contrast, the delayed feeding group (\\>24 hours) maintains fasting on the day of the procedure and begins a liquid diet the following day. The study will compare the early and delayed feeding groups in terms of early post-procedural adverse events (occurring within 24 hours after the procedure)(e.g., bleeding, perforation, post-coagulation syndrome), patient satisfaction, and delayed post-procedural adverse events (occurring more than 24 hours after the procedure).",[55,56],"Endoscopic Submucosal Dissection","Colorectal Neoplasms",[58,59,60],"colorectum","endoscopic submucosal dissection","feeding","2026-06-14",{"date":63,"type":33},"2026-06-17",{"date":65,"type":33},"2025-02-01",{"date":67,"type":21},"2026-12-30",{"name":39,"class":40},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":41},"100598582","phase-2-bolstering-outcomes-after-induction-with-osimertinib-plus-chemotherapy-through-optimized-site-directed-primary-tumor-therapy-boost-trial-100598582","NCT07073365","Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)","A Prospective Cohort Observational Study of Local Therapy for the Primary Tumor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer Following Osimertinib Plus Chemotherapy (FLAURA2 Regimen)","BOOST","\\\u003CInclusion Criteria\\>\n\nParticipants must meet all of the following criteria to be eligible:\n\n1. Age ≥ 20 years at the time of consent.\n2. Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).\n3. Presence of activating EGFR mutation (exon 19 deletion or L858R).\n4. Stage IV (metastatic) NSCLC at initial diagnosis.\n5. Completion of four cycles of first-line osimertinib plus platinum-based chemotherapy (FLAURA2 regimen).\n6. Radiologic evidence of disease control (complete response, partial response, or stable disease) after systemic therapy.\n7. Residual primary lung tumor suitable for local therapy (surgery or radiotherapy), as determined by multidisciplinary evaluation.\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n9. Adequate organ function based on institutional laboratory criteria.\n10. Ability to understand and willingness to provide written informed consent.\n\n\\\u003CExclusion Criteria\\>\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Radiologic or clinical evidence of progressive disease during first-line osimertinib-chemotherapy.\n2. Extensive, unresectable metastatic disease not amenable to local therapy.\n3. Untreated or clinically unstable brain metastases.\n4. Known contraindications to surgery or radiotherapy.\n5. Active second malignancy requiring concurrent treatment.\n6. Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results.\n7. Pregnancy or breastfeeding at the time of enrollment.","20 Years",{"count":79,"type":21},70,[81],"PHASE2","This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.",[84,85],"Non-Small Cell Lung Cancer","Epidermal Growth Factor Receptor",[84,87,88,89,90,91,92],"EGFR Mutation","FLAURA2","Osimertinib","Local Therapy","Surgery","Radiotherapy","2025-12-22",{"date":95,"type":33},"2025-12-30",{"date":97,"type":33},"2025-07-01",{"date":99,"type":21},"2031-06-30",{"name":39,"class":40},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100583605","efficacy-and-safety-of-discontinuing-5-asa-in-patients-with-inflammatory-bowel-disease-100583605","NCT06878495","Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease","Optimizing IBD Management: A Comparative Study on the Efficacy and Safety of 5-ASA De-escalation in Patients With Ulcerative Colitis and Crohn's Disease on Stable Biologic or Immunomodulator Therapy","Inclusion Criteria\n\n1. Diagnosis\n\n   o Patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) based on standard diagnostic criteria, including clinical, endoscopic, and histologic findings.\n2. Treatment Status\n\n   * Patients who have been continuously treated with biologic agents (e.g., anti-TNF agents, integrin inhibitors, JAK inhibitors) or immunomodulators (e.g., azathioprine, methotrexate) for at least three months.\n   * Patients who have been on a stable dose of 5-ASA (mesalamine) for at least three months before study enrollment.\n3. Disease Activity\n\n   o Patients in clinical remission for at least three months, as defined by the Mayo score for UC or the Crohn's Disease Activity Index (CDAI) for CD.\n4. Age\n\n   o Adults aged 19 years or older.\n5. Informed Consent\n\n   o Patients capable of providing written informed consent for study participation.\n6. Compliance with Study Protocol\n\n   o Patients who can adhere to the study protocol and visit schedule.\n7. General Health Condition\n\n   o Patients without severe medical conditions that could impact the study or patient safety, such as significant cardiac, renal, or hepatic diseases.\n8. No recent medication changes\n9. Patients who have not had any new prescriptions or dose adjustments of corticosteroids, antibiotics, or other medications that could affect IBD within a specified period (e.g., four weeks) before enrollment.\n\nExclusion Criteria\n\n1. Patients with severe active UC or CD at the time of study enrollment.\n2. Patients who have been recently hospitalized for IBD-related reasons or undergone IBD-related surgery within three months before enrollment.\n3. Patients who have had dose modifications of biologics, immunomodulators, or corticosteroids for IBD within three months before enrollment.\n4. Patients receiving concomitant therapy with other medications that may affect disease activity (e.g., additional anti-inflammatory agents, IBD-related antibiotics).\n5. Patients with severe cardiac, renal, or hepatic disease or other medical conditions that could interfere with the study.\n6. Pregnant or breastfeeding women.\n7. Patients with known allergies or intolerance to 5-ASA or related medications.\n8. Patients currently participating in another clinical study that may interfere with this study.\n9. Patients unable to provide informed consent or unlikely to comply with the study protocol and visit schedule.\n10. Patients with a history of non-response or intolerance to their current biologic or immunomodulator therapy.\n11. Patients with a history of severe psychiatric disorders that may affect their ability to participate in the study.",{"count":109,"type":21},100,[24],"This study aims to evaluate the long-term outcomes of discontinuing 5-ASA in UC and CD patients receiving stable biologic or immunomodulator therapy using a prospective cohort based in the Busan-Ulsan-Gyeongnam region. It seeks to determine whether discontinuing 5-ASA is a safe treatment strategy in modern IBD management.",[113,114,115],"Ulcerative Colitis (UC)","Crohn's Disease","Inflammatory Bowel Disease (IBD)",[117,118,119],"5-ASA Discontinuation","Inflammatory Bowel Disease","Biologic Therapy","NOT_YET_RECRUITING","2025-05-27",{"date":123,"type":33},"2025-05-29",{"date":125,"type":21},"2025-06-15",{"date":127,"type":21},"2025-12-31",{"name":39,"class":40},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":149,"locationsCount":4},"100121995","the-randomized-study-of-dasatinib-and-high-dose-imatinib-600mg-in-suboptimal-responder-100121995","NCT00854841","The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder","Randomized, Open Label Study of Dasatinib (100mg qd) vs. High-Dose Imatinib (600mg) in Patients With Chronic Phase CML Who Have Had Suboptimal Response After 3-18 Months of Therapy With Imatinib (400mg)","Inclusion Criteria:\n\n1. Signed written informed consent, at least 18 years old\n2. Adequate hepatic renal function\n3. Dasatinib naïve patients\n4. Patients with cytogenetically and\u002For molecularly confirmed Philadelphia chromosome or BCR-ABL positive CP-CML who have been treated with standard dose of imatinib.\n5. ECOG status: 0-2\n6. And one of following criteria for imatinib suboptimal response 1)CP-CML patients who have failed to achieve a CHR at 3 months or MCyR at 6 months of therapy with imatinib 400mg daily. 2)CP-CML patients who have failed to achieve a CCyR at 12 months with imatinib 400mg daily 3)CP-CML patients who have failed to achieve a MMoR (less than 3 log reduction) at 18 months with imatinib 400mg daily 4)CP-CML patients who have lost molecular response by an increase of BCR-ABL more than 10 times regardless treatment duration.\n\nExclusion Criteria:\n\n1. Concurrent malignancy\n2. Patients who have received SCT\n3. Allergy or hypersensitivity reaction to the study drugs\n4. Female who are pregnant or breast feeding.\n5. T315I mutation\n6. History of significant bleeding disorder\n7. Women of child bearing potential\n8. Uncontrolled or significant CVS disease: IHD. CHF\n9. Prior imatinib\\>400mg, imatinib\\>18 months\n10. Intolerance to imatinib 400mg","EXPANDED_ACCESS","Research Hypothesis:\n\nTreatment with dasatinib 100 mg QD is superior to imatinib 600 mg QD in terms of complete cytogenetic response (CCyR) in chronic phase (CP) Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) subjects who are imatinib failures or who have achieved only a suboptimal response after 3-18 months (12-77 weeks) of therapy with imatinib 400 mg.\n\nPrimary Objective:\n\nThe primary objective of this study is to compare the rate of CCyR of dasatinib (100mg QD) to high-dose imatinib (600 mg QD) therapy at 6 months after randomization in CP Ph+ CML subjects who are imatinib failures or who have achieved only a suboptimal response after 3 - 18 months of imatinib monotherapy at 400 mg\u002Fday.",[139],"Chronic Myeloid Leukemia",[141,142,143,144],"CML","suboptimal response","dasatinib","imatinib","AVAILABLE","2009-03-02",{"date":148,"type":21},"2009-03-03",{"name":39,"class":40},""]